Proton-Pump Inhibitors and Risk of Calcium Pyrophosphate Deposition in a Population-Based Study.

ABSTRACT:

Objective

There are no proven effective medical treatments to prevent calcium pyrophosphate crystal deposition (CPPD). Hypomagnesemia is a known CPPD risk factor. The present study was undertaken to carry out a real-world epidemiologic study on proton-pump inhibitor (PPI) use, which can cause hypomagnesemia, and CPPD risk.

Methods

We conducted a time-stratified, propensity score (PS)-matched cohort study using the UK-based IQVIA Medical Research Data. We compared risk of incident CPPD among PPI users versus H₂ blocker users using Cox proportional hazards models. We used greedy matching of incident PPI users 1:1 to incident histamine receptor 2 (H₂ ) blocker users in 1-year cohort accrual blocks. Subjects were censored at time of drug switch. We evaluate

SUBMITTER: Liew JW 

PROVIDER: S-EPMC9440954 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature